Financial Data and Key Metrics Changes - The company reported total revenue of $15.7 million, a decrease of $900,000 or 5% year over year [14] - Gross profit decreased by $2.4 million or 20% to $9.4 million compared to the previous year [15] - Gross margin was 60.1% of revenue, down from 71.5% in the previous year [17] - Net loss attributable to stockholders was $11.7 million or $8.03 per share, compared to a net loss of $20 million or $30.93 per share for the previous year [18] - Adjusted EBITDA loss was $8.8 million compared to an adjusted EBITDA loss of $4.1 million for the previous year [18] Business Line Data and Key Metrics Changes - Total systems and subscription revenue grew by 20% in the second quarter [5] - Cash system sales in the U.S. represented 65% of total U.S. system sales, up from 58% the previous year [9] - Revenue from the company's internal lease program, Venus Prime, accounted for approximately 37% of total systems revenue, compared to 34% in the prior year [15] Market Data and Key Metrics Changes - U.S. revenue increased by 5% year over year, while international sales declined by 18% [6] - The company noted that customer financing pressures and economic uncertainty are impacting system adoption [7] - The international business is particularly exposed to macroeconomic headwinds, including tariffs affecting distributor demand [8] Company Strategy and Development Direction - The company announced a definitive agreement to sell the Venus Hair business for $20 million, allowing a focus on the global medical aesthetics business [10] - The strategic transaction is expected to improve revenue growth, lower operating expenses, and enhance cash flow [10] - The company aims to transition to higher quality cash revenues and is focused on launching a new body device by early 2026 [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed that the year-over-year results indicate potential revenue stabilization despite a challenging capital equipment environment [6] - The company is managing cash burn through disciplined cost management and targeted investments for long-term growth [13] - Due to ongoing market conditions and trade disruptions, the company is not providing full-year 2025 financial guidance [20] Other Important Information - The company has made significant progress in improving its balance sheet, with cash and cash equivalents of $4.9 million and total debt obligations reduced to approximately $34.3 million [19] - The company exchanged $17.5 million of subordinated convertible notes for preferred stock, enhancing its financial profile [20] Summary of Q&A Session - There was no live Q&A session due to international travel conflicts, and all follow-up questions were directed to the investor inquiries email address [21]

Core Viewpoint - Venus Concept Inc. has entered into a definitive agreement to sell its Venus Hair business to MHG Co. Ltd for $20 million in cash, which is expected to enhance the company's financial condition and support strategic growth initiatives [1][2][3] Group 1: Transaction Details - The transaction is valued at $20 million, subject to customary working capital adjustments [1] - The sale includes the portfolio of hair restoration and hair transplant technologies, related equipment, services, and intellectual property, specifically for ARTAS and NeoGraft [2][3] - The transaction is anticipated to close in the third quarter of 2025, pending certain closing conditions [3] Group 2: Financial Impact - The revenue from the sale of ARTAS and NeoGraft systems, procedure kits, and warranty revenue was approximately $12.5 million in fiscal year 2024 [3] - Cash used in operations related to the hair restoration and transplant businesses totaled approximately $6.7 million in fiscal year 2024 [3] Group 3: Strategic Rationale - The CEO of Venus Concept stated that the transaction allows the company to focus on its global medical aesthetics business, which is expected to improve revenue growth and lower operating expenses [2] - Meta Healthcare Group aims to leverage the acquired technologies to expand its hair loss-related business areas and enhance R&D and manufacturing capabilities [2][5]

Financial Data and Key Metrics Changes - Total revenue for Q4 2024 was $15.8 million, down $2.4 million or 13% year-over-year, primarily due to a mid-teens decline in systems revenue and a mid-single-digit decline in procedure-related products and service revenue [6][24] - Lease revenue declined by $3.5 million or 58% year-over-year in Q4, offsetting mid-teens growth in cash system sales [7][24] - Cash system sales in the U.S. increased 27% year-over-year, representing 87% of total U.S. system sales in Q4 compared to 58% last year [8][10] - Gross profit decreased by $1.2 million or 10% to $10.9 million, with gross margin improving to 69.1% from 66.5% year-over-year [29] Business Line Data and Key Metrics Changes - Systems revenue from internal lease programs decreased to approximately 20% in Q4 2024 from 41% in the prior year, reflecting a strategic shift towards cash sales [25] - Cash systems revenue and sales of products and services increased by 10% year-over-year in Q4 [24][25] - The company achieved a 14% reduction in cash used in operations year-over-year in 2024, indicating progress in operational efficiency [15] Market Data and Key Metrics Changes - The decline in global systems adoption was attributed to macroeconomic headwinds, including customer financing pressures and economic uncertainty [9][10] - Sales through distributors more than doubled year-over-year in Q4, particularly in the APAC and EMEA regions [12] Company Strategy and Development Direction - The company is focused on transitioning to higher quality cash revenues and has made significant progress in restructuring its debt obligations, reducing total debt from $74.9 million to approximately $39.7 million [17][20] - The strategic initiatives include cost reductions, shifting to cash sales, and working capital management, which are expected to enhance long-term profitability [14][15] - The company plans to launch a new body device in the second half of 2025, which is anticipated to drive growth [54] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that while the strategic transition is largely complete, macroeconomic challenges will continue to impact quarterly performance [14][36] - The company is not providing full-year 2025 financial guidance but expects total revenue for Q1 2025 to be at least $14 million [36] Other Important Information - A 1 for 11 reverse stock split was announced, with the company's common stock trading on an adjusted basis starting March 4, 2025 [21] - The company secured an amendment to its bridge loan agreement, increasing financing capacity by $10 million [22][34] Q&A Session Summary Question: Can you characterize the expected normalized business profile going forward? - Management indicated that while predicting the macroeconomic environment is challenging, they expect performance to improve compared to 2024, with less decline anticipated [40][42] Question: How is the Venus Hair business performing? - Management expressed satisfaction with the performance of the Venus Hair business, particularly the Venus ARTAS Robot, and noted ongoing R&D innovations [44][46] Question: What is the strategy for top-line growth in 2025? - The focus will be on establishing a normal rhythm of orders with new distribution partners internationally and launching a new body system in the U.S. [52][54] Question: Are there further cost-cutting measures available? - Management stated that the infrastructure is efficient, and the focus is on increasing sales rather than further cost reductions [56][58] Question: How do tariffs affect the business? - Products are manufactured in both the U.S. and Israel, with no substantial near-term impact expected from tariffs at this time [60]